Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.

Encalada Ventura MA, van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2727-31. doi: 10.1128/AAC.02830-15. Print 2016 May.

2.

Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care.

van Wanrooy MJ, Rodgers MG, Span LF, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Ther Drug Monit. 2016 Jun;38(3):313-8. doi: 10.1097/FTD.0000000000000284.

PMID:
26845112
3.

Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease.

van der Elst KC, Brouwers CH, van den Heuvel ER, van Wanrooy MJ, Uges DR, van der Werf TS, Kosterink JG, Span LF, Alffenaar JW.

Ther Drug Monit. 2015 Dec;37(6):766-71. doi: 10.1097/FTD.0000000000000235.

PMID:
26565789
4.

Limited-sampling strategies for anidulafungin in critically ill patients.

van Wanrooy MJ, Proost JH, Rodgers MG, Zijlstra JG, Uges DR, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Feb;59(2):1177-81. doi: 10.1128/AAC.03375-14. Epub 2014 Dec 8.

5.

Inflammation is associated with voriconazole trough concentrations.

van Wanrooy MJ, Span LF, Rodgers MG, van den Heuvel ER, Uges DR, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2014 Dec;58(12):7098-101. doi: 10.1128/AAC.03820-14. Epub 2014 Sep 15.

6.

Low but sufficient anidulafungin exposure in critically ill patients.

van Wanrooy MJ, Rodgers MG, Uges DR, Arends JP, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2014;58(1):304-8. doi: 10.1128/AAC.01607-13. Epub 2013 Oct 28.

7.

Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method.

van Wanrooy MJ, Santoe RN, van der Elst KC, Wilmer CM, van Hateren K, Wessels AM, Greijdanus B, Alffenaar JW, Uges DR.

Ther Drug Monit. 2013 Dec;35(6):778-84. doi: 10.1097/FTD.0b013e31829591a7.

PMID:
24081203

Supplemental Content

Loading ...
Support Center